Biopharmaceutical CMO & CRO Market by Source (Mammalian, Non-Mammalian), Service Type (Contract Manufacturing, Contract Research), Product, Scale of Operation, Therapeutic Applications - Global Forecast 2023-2030

Biopharmaceutical CMO & CRO Market by Source (Mammalian, Non-Mammalian), Service Type (Contract Manufacturing, Contract Research), Product, Scale of Operation, Therapeutic Applications - Global Forecast 2023-2030


The Biopharmaceutical CMO & CRO Market is projected to reach USD 260.65 billion by 2030 from USD 69.18 billion in 2022, at a CAGR of 18.03% during the forecast period.

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Biopharmaceutical CMO & CRO Market.
  • Based on Source, market is studied across Mammalian and Non-Mammalian. The Mammalian is projected to witness significant market share during forecast period.
  • Based on Service Type, market is studied across Contract Manufacturing and Contract Research. The Contract Manufacturing is projected to witness significant market share during forecast period.
  • Based on Product, market is studied across Biologics and Biosimilars. The Biosimilars is projected to witness significant market share during forecast period.
  • Based on Scale of Operation, market is studied across Clinical and Commercial. The Commercial is projected to witness significant market share during forecast period.
  • Based on Therapeutic Applications, market is studied across Cardiovascular Diseases, Infectious Disease, Neurology, Oncology, Ophthalmology, and Respiratory Disorder. The Oncology is projected to witness significant market share during forecast period.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.
Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Biopharmaceutical CMO & CRO Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Biopharmaceutical CMO & CRO Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Biopharmaceutical CMO & CRO Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., arexel International Corporation, Baxter International Inc., Boehringer Ingelheim Biopharmaceuticals GmbH, Boehringer Ingelheim GmbH, Catalent, Inc., Charles River Laboratories International, Inc., Eurofins Scientific Limited, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., ICON Plc, KBI Biopharma, Inc., KEMWELL BIOPHARMA PRIVATE LIMITED, Laboratory Corporation of America Holdings, Lonza Group AG, NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC, Patheon Inc., Rentschler Biopharma SE, and Sterling Pharma Solutions.

The report offers valuable insights on the following aspects:
  1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.
  2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.
  3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.
  4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.
  5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
  1. What is the market size and forecast for the Biopharmaceutical CMO & CRO Market?
  2. Which products, segments, applications, and areas hold the highest investment potential in the Biopharmaceutical CMO & CRO Market?
  3. What is the competitive strategic window for identifying opportunities in the Biopharmaceutical CMO & CRO Market?
  4. What are the latest technology trends and regulatory frameworks in the Biopharmaceutical CMO & CRO Market?
  5. What is the market share of the leading vendors in the Biopharmaceutical CMO & CRO Market?
  6. Which modes and strategic moves are suitable for entering the Biopharmaceutical CMO & CRO Market?


Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Biopharmaceutical CMO & CRO Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising need for outsourced service in pharmaceutical and biotechnology sector
5.1.1.2. Potential demand for macromolecular therapeutics
5.1.1.3. Ongoing research and development activities in biopharmaceutical sector
5.1.2. Restraints
5.1.2.1. Issues pertinent to fewer outsource suppliers and less competition
5.1.3. Opportunities
5.1.3.1. Penetration of advanced technology in the biotechnology field
5.1.3.2. Emergence of Cell and Gene Therapies for Targeted Treatment
5.1.4. Challenges
5.1.4.1. Concern associated with accountability and quality control of CMO and CRO
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization
6. Biopharmaceutical CMO & CRO Market, by Source
6.1. Introduction
6.2. Mammalian
6.3. Non-Mammalian
7. Biopharmaceutical CMO & CRO Market, by Service Type
7.1. Introduction
7.2. Contract Manufacturing
7.3. Contract Research
8. Biopharmaceutical CMO & CRO Market, by Product
8.1. Introduction
8.2. Biologics
8.3. Biosimilars
9. Biopharmaceutical CMO & CRO Market, by Scale of Operation
9.1. Introduction
9.2. Clinical
9.3. Commercial
10. Biopharmaceutical CMO & CRO Market, by Therapeutic Applications
10.1. Introduction
10.2. Cardiovascular Diseases
10.3. Infectious Disease
10.4. Neurology
10.5. Oncology
10.6. Ophthalmology
10.7. Respiratory Disorder
11. Americas Biopharmaceutical CMO & CRO Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Biopharmaceutical CMO & CRO Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Biopharmaceutical CMO & CRO Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
15. Competitive Portfolio
15.1. Key Company Profiles
15.1.1. AbbVie, Inc.
15.1.2. arexel International Corporation
15.1.3. Baxter International Inc.
15.1.4. Boehringer Ingelheim Biopharmaceuticals GmbH
15.1.5. Boehringer Ingelheim GmbH
15.1.6. Catalent, Inc.
15.1.7. Charles River Laboratories International, Inc.
15.1.8. Eurofins Scientific Limited
15.1.9. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
15.1.10. ICON Plc
15.1.11. KBI Biopharma, Inc.
15.1.12. KEMWELL BIOPHARMA PRIVATE LIMITED
15.1.13. Laboratory Corporation of America Holdings
15.1.14. Lonza Group AG
15.1.15. NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC
15.1.16. Patheon Inc.
15.1.17. Rentschler Biopharma SE
15.1.18. Sterling Pharma Solutions
15.2. Key Product Portfolio
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings